BCX4430

BCX4430, also known as galidesivir, is an experimental broad-spectrum antiviral nucleotide analog developed by BioCryst Pharmaceuticals. It is a prodrug intended to be metabolized intracellularly into an active triphosphate that inhibits viral RNA-dependent RNA polymerases, thereby blocking viral RNA synthesis.

Preclinical studies have shown activity against a range of RNA viruses, including filoviruses such as Ebola and Marburg, arenaviruses, coronaviruses, and flaviviruses. In cell culture and animal models, BCX4430 reduced viral replication and, in some nonhuman primate studies, improved survival when treatment was started after infection.

Development and regulatory status: BCX4430 has been the subject of collaboration with U.S. government institutions for outbreak preparedness. It has undergone early-phase clinical testing to evaluate safety and tolerability in humans. As of the latest public information, there are no approved indications or commercial products based on BCX4430, and comprehensive clinical efficacy data have not been published for regulatory approval.

Mechanism and pharmacology notes: The drug is a nucleotide analog prodrug activated inside cells to inhibit RdRP. Its broad-spectrum activity depends on the ability of the active metabolite to interfere with RNA synthesis by viral polymerases. The exact clinical efficacy and safety profile in humans remain to be established.